<DOC>
	<DOCNO>NCT02040597</DOCNO>
	<brief_summary>The study perform characterize pharmacokinetics glycopyrrolate bromide single administration CHF 5993 pressurise Metered Dose Inhaler ( pMDI ) subject different level renal impairment comparison match healthy volunteer . Moreover , safety tolerability study drug also evaluate .</brief_summary>
	<brief_title>A Study Investigate Pharmacokinetics , Safety Tolerability CHF 5993 pMDI Subjects With Renal Impairment .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Healthy volunteer Subjects mild , moderate severe renal impairment pregnant lactate woman positive HIV hepatitis serology history drug abuse history hypersensitivity product use trial smoker respiratory disease asthma COPD clinically relevant concomitant disease may introduce risk subjects'safety presence kidney stone dialysis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>